Loading
A phase 3 trial of Durvalumab in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants is a phase 3 interventional study registered as NCT05943106 by AstraZeneca, with 100 participants enrolled, started 2023-08-11 and due to reach its primary completion in 2025-06-16. Interventions recorded: Durvalumab and BCG.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/